OncoSynergy announced that it has submitted an FDA application for a first-in-human trial of its Orphan Drug designated experimental therapeutic OS2966 for malignant brain cancer. Read press release > click here
© 2021 OncoSynergy. All Rights Reserved by OncoSynergy, Inc